Document Detail


Ritonavir for preventing perinatal HIV transmission.
MedLine Citation:
PMID:  11366688     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A Thai study on short-term Ritonavir treatment to interrupt perinatal HIV transmission was presented at 6th CROI by S. Limpongsanurak. The safety, tolerability, and efficacy of Ritonavir were examined in a phase IV open-label study involving 86 pregnant women. Ritonavir was given two weeks before their due dates, with dosages gradually increased up to 600 mg twice daily. Breast-feeding was not permitted. Seventy-four mothers completed the study, and perinatal HIV transmission rate was 9.46 percent. In comparison, the rate of perinatal transmission without treatment in the U.S. is 25 percent. Researchers credit Ritonavir with reducing maternal viral load and the rate of perinatal HIV transmission.
Authors:
L Hanna
Related Documents :
12681888 - Human immunodeficiency virus infection in pregnancy.
2688178 - Aids and the lung. 1--aids, aprons, and elbow grease: preventing the nosocomial spread ...
1449788 - Perinatal hiv transmission facts and controversies.
8923288 - Significance of placental damage in vertical transmission of human immunodeficiency virus.
1204968 - Epidemiological distribution and significance of anti-hbs.
8091728 - Is the apparent outbreak of hepatitis a in belgian hemophiliacs due to a loss of previo...
Publication Detail:
Type:  Newspaper Article    
Journal Detail:
Title:  BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation     Volume:  12     ISSN:  1058-708X     ISO Abbreviation:  BETA     Publication Date:  1999 Apr 
Date Detail:
Created Date:  2000-05-31     Completed Date:  2000-05-31     Revised Date:  2014-08-25    
Medline Journal Info:
Nlm Unique ID:  9113964     Medline TA:  BETA     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  20     Citation Subset:  X    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials, Phase IV as Topic
Female
HIV Infections / transmission*
HIV Protease Inhibitors / therapeutic use*
Humans
Infant
Infant, Newborn
Infectious Disease Transmission, Vertical / prevention & control*
Pregnancy
Ritonavir / therapeutic use*
Thailand
Viral Load
Chemical
Reg. No./Substance:
0/HIV Protease Inhibitors; O3J8G9O825/Ritonavir

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Promising findings from the PETRA study of perinatal transmission.
Next Document:  HAART appears to prevent mother-to-child HIV transmission.